A Target Occupancy Study with Ritlecitinib
A Target Occupancy Study with Ritlecitinib. An Open Label, Phase 1, Two-Arm Study to Assess
Target Occupancy and Functional Inhibition of JAK3 and TEC Kinases by Single Doses of Ritlecitinib in Healthy Adult Participants.
Category & Conditions: Immune System Diseases and Conditions
Medicine: ritlecitinib (PF-06651600)
ClinicalTrials.gov Identifier (NCT): NCT05128058
Protocol ID: B7981045
PrintDownloadOpen Plain Language Summary Result: Click here